CEL-SCI says Oral Oncology accepts Multikine Phase 3 data showing survival benefit in low PD-L1 oral cancer patients - CVM News | RalliesCEL-SCI says Oral Oncology accepts Multikine Phase 3 data showing survival benefit in low PD-L1 oral cancer patients
C
CVM• Oral Oncology accepts Phase 3 Multikine data
- CEL-SCI reported a leading oncology journal accepted for publication new Phase 3 Multikine data in head and neck cancer.
- Results were previously generated in the completed trial; detailed findings will be disclosed when the paper is published.
- In a predefined underserved subgroup, Multikine paired with standard care was associated with better long-term survival than standard care alone.
- The company is preparing to start enrollment in a 212-patient confirmatory registration study to validate the survival benefit.
